These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29686025)

  • 1. Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
    Chang A; Llinas EJ; Chen K; Llinas RH; Marsh EB
    Stroke; 2018 Jun; 49(6):1521-1524. PubMed ID: 29686025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
    Amlie-Lefond C; Shaw DWW; Cooper A; Wainwright MS; Kirton A; Felling RJ; Abraham MG; Mackay MT; Dowling MM; Torres M; Rivkin MJ; Grabowski EF; Lee S; Kurz JE; McMillan HJ; Barry D; Lee-Eng J; Ichord RN
    Stroke; 2020 Feb; 51(2):542-548. PubMed ID: 31842706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
    Marsh EB; Gottesman RF; Hillis AE; Urrutia VC; Llinas RH
    Medicine (Baltimore); 2013 Nov; 92(6):317-323. PubMed ID: 24145699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
    James B; Chang AD; McTaggart RA; Hemendinger M; Mac Grory B; Cutting SM; Burton TM; Reznik ME; Thompson B; Wendell L; Mahta A; Siket M; Madsen TE; Sheth KN; Nouh A; Furie KL; Jayaraman MV; Khatri P; Yaghi S
    J Neurol Neurosurg Psychiatry; 2018 Aug; 89(8):866-869. PubMed ID: 29487169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of Symptomatic Intracerebral Hemorrhage Related to Intravenous tPA Administered Over Telestroke Within 4.5-Hour Window.
    Al Kasab S; Orabi MY; Harvey JB; Turner N; Aysse P; Debenham E; Holmstedt CA
    Telemed J E Health; 2018 Oct; 24(10):749-752. PubMed ID: 29369743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
    Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED;
    Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
    Shah K; Clark A; Desai SM; Jadhav AP
    Neurocrit Care; 2022 Feb; 36(1):123-129. PubMed ID: 34228264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.
    Shahjouei S; Tsivgoulis G; Bavarsad Shahripour R; Jones GM; Alexandrov AV; Zand R
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2685-93. PubMed ID: 26542821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
    Menon BK; Saver JL; Prabhakaran S; Reeves M; Liang L; Olson DM; Peterson ED; Hernandez AF; Fonarow GC; Schwamm LH; Smith EE
    Stroke; 2012 Sep; 43(9):2293-9. PubMed ID: 22811458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
    Orlando A; Wagner JC; Fanale CV; Whaley M; McCarthy KL; Bar-Or D
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):969-76. PubMed ID: 26856464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke.
    Messé SR; Pervez MA; Smith EE; Siddique KA; Hellkamp AS; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Schwamm LH
    Stroke; 2013 May; 44(5):1354-9. PubMed ID: 23493734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
    Vellimana AK; Yarbrough CK; Blackburn S; Strom RG; Pilgram TK; Lee JM; Grubb RL; Rich KM; Chicoine MR; Dacey RG; Derdeyn CP; Zipfel GJ
    Neurosurgery; 2014 Mar; 74(3):254-61. PubMed ID: 24335814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.
    Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB
    Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IER-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Thrombectomy for Stroke.
    Cappellari M; Mangiafico S; Saia V; Pracucci G; Nappini S; Nencini P; Konda D; Sallustio F; Vallone S; Zini A; Bracco S; Tassi R; Bergui M; Cerrato P; Pitrone A; Grillo F; Saletti A; De Vito A; Gasparotti R; Magoni M; Puglielli E; Casalena A; Causin F; Baracchini C; Castellan L; Malfatto L; Menozzi R; Scoditti U; Comelli C; Duc E; Comai A; Franchini E; Cosottini M; Mancuso M; Peschillo S; De Michele M; Giorgianni A; Delodovici ML; Lafe E; Denaro MF; Burdi N; Internò S; Cavasin N; Critelli A; Chiumarulo L; Petruzzellis M; Doddi M; Carolei A; Auteri W; Petrone A; Padolecchia R; Tassinari T; Pavia M; Invernizzi P; Turcato G; Forlivesi S; Ciceri EFM; Bonetti B; Inzitari D; Toni D;
    Stroke; 2019 Apr; 50(4):909-916. PubMed ID: 31233386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.